Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs JANX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLTX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–2 Matrix Metrics)

MLTX Overall Winner 6-Pillar Tally: MLTX 4 – 1 JANX (1 Tie) Matrix Metrics: MLTX 5 – 2 JANX

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Janux Therapeutics, Inc. (JANX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas JANX carries 45.0/100 (HOLD) at $10.97 (N/M Forward P/E, -599.3% operating margin).

  • Composite vs. Pillar Nuance: While JANX currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -599.3% operating margin) and revenue trajectory (+0.0% vs. -7.1% YoY).
  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile JANX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs JANX
MLTX NASDAQ Head-to-Head Winner
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
JANX NASDAQ
Janux Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$10.97
-3.47% 1D
Market Cap $703.3M
TTM Revenue $23M
Forward P/E N/M
Beta / 30D Vol 0.73β · 118% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 35.0 Fund 51.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.0%), weak momentum, RSI 28
RSI-14: 27.7 · SMA20: $15.66 · SMA50: $16.61

6-Pillar Scorecard Institutional Category Breakdown (MLTX 4 – 1 JANX)

Columns: Metric · MLTX · JANX
1. Valuation Multiples JANX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.3x
2. Growth & Scale MLTX
Revenue Growth (YoY) +0.0% -7.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $23M
Market Cap $1.1B $703.3M
3. Profitability & Quality MLTX
Gross Margin N/A N/A
Operating Margin 0.0% -599.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -81.5% -10.6%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$244M -$54M
Cash Flow Margin N/A N/A
Net Cash / Leverage $278M Net Cash $21M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 111.8% (7th %ile) 57.7% (11th %ile)
Put/Call OI Skew N/A 148.09x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (5) vs JANX (2)
Institutional Metric MLTX JANX Criterion Row Edge
Market Capitalization
Scale
$1.1B $703.3M Larger Scale MLTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -7.1% Higher Growth MLTX
Operating Margin (TTM)
Profitability
0.0% -599.3% Higher Margin MLTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-81.5% -10.6% Higher ROE JANX
52-Week Range Position
Momentum
17% ($9–$23) 1% ($11–$35) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 0.73β · 118% Vol Lower Realized Risk MLTX
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 45.0 / 100 (HOLD) Higher Composite JANX
Trailing 12M Revenue (USD)
Operating Scale
N/A $23M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) -$54M ($21M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +57.61 pp
MLTX: +24.08% · JANX: -33.53%
3M Horizon MLTX +7.81 pp
MLTX: -27.48% · JANX: -35.29%
6M Horizon JANX +6.15 pp
MLTX: -27.92% · JANX: -21.77%
1Y Horizon MLTX +54.38 pp
MLTX: -5.65% · JANX: -60.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs JANX. Trailing 12-month operating profitability (MLTX 0.0% vs JANX -599.3%) and valuation multiples (MLTX N/M vs JANX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
JANX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$23M
Gross MarginN/A
Op. Margin-599.3%
ROE / Fwd P/E-10.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JANX BREAKDOWN
51d in phase · OBV DISTRIBUTION
Current IV 57.7%
IV Percentile 11th %ile
Put/Call OI Skew 148.09x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact JANX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
JANX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $703.3M market capitalization and -599.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs JANX Key Questions & Quantitative Answers

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Janux Therapeutics, Inc. (JANX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas JANX carries 45.0/100 (HOLD) at $10.97 (N/M Forward P/E, -599.3% operating margin). Composite vs. Pillar Nuance: While JANX currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -599.3% operating margin) and revenue trajectory (+0.0% vs. -7.1% YoY). Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile JANX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MLTX leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with JANX at -7.1% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (N/A gross margin, -599.3% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $23M for JANX. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JANX.

JANX screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas JANX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus JANX (-10.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, JANX carries 57.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 148.09x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.73β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.